Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies

Min Chul Choi*, Yong Wha Moon*, Sang Geun Jung1, Hyun Park1, Won Duk Joo1, Seung Hun Song1, Chan Lee1, Gwangil Kim3, and Kyoung Ah Kim4

1Comprehensive Gynecologic Cancer Center, 2Hematology and Oncology, Departments of 3Pathology and 4Radiology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

Purpose: We evaluated the efficacy and safety of pembrolizumab in patients with recurrent gynecologic cancers in real-world practice.

Materials and Methods: We conducted a retrospective, single-institution study of patients with recurrent gynecologic malignancies treated with pembrolizumab. The primary endpoints were the objective response rate (ORR) and safety.

Results: Thirty-one patients treated with pembrolizumab were included. The primary disease sites were the uterine cervix (n=18), ovaries (n=8), and uterine corpus (n=5). Fifteen of the 31 patients (48%) had an Eastern Cooperative Oncology Group performance status of ≥2. The median number of prior chemotherapy lines was 2 (range, 1–6), and 14 of 31 patients (45%) had received ≥ 3 prior lines of chemotherapy. The overall ORR was 22.6%: specifically, 22.3% (4 of 18 patients), 12.5% (1 of 8 patients), and 40% (2 of 5 patients) for cervical, ovarian, and endometrial cancers, respectively. During a median follow-up of 4.7 months (range, 0.2–35.3), the median time to response was 1.9 months (range, 1.4–5.7). The median duration of response was not reached (range, 8.8-not reached). The median progression-free survival was 2.5 months (95% confidence interval, 1.7-not reached). Adverse events occurred in 20 patients (64.5%), and only 3 (9.7%) were grade ≥3. There was one case of suspicious treatment-related mortality, apart from which most adverse events were manageable.

Conclusion: In real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials.

Key Words: Gynecologic neoplasms, pembrolizumab, recurrence

INTRODUCTION

Gynecologic malignancies, including ovarian cancer, endometrial cancer, and cervical cancer, are major causes of death due to cancer among women worldwide.1 Ovarian cancer is typically diagnosed at an advanced stage. In about 70–80% of patients with advanced ovarian cancer, cytoreductive surgery with platinum-based chemotherapy often leads to complete remission; however, most patients experience recurrence and eventually develop chemoresistance.2 While early-stage endometrial or cervical cancer can be cured, by local therapy, such as surgery or radiotherapy with concurrent or sequential chemotherapy,3 advanced or recurrent tumors, for which only first- or second-line systemic therapy has been established, are incurable. Therefore, there is an urgent need for more effective
anticancer therapeutic strategies for advanced or recurrent gynecologic cancers.

Immunotherapy has long been studied as a promising anticancer treatment strategy. Immune checkpoint inhibitors (ICIs), including programmed cell death-1/ligand-1 (PD-1/PD-L1) inhibitors, such as pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab, and cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, such as ipilimumab, work by blocking the pathways that downregulate the activity of T lymphocytes. In recent years, various ICIs have been found to provide improvements in overall survival (OS) for various advanced cancers, including recurrent gynecologic cancers. Virus-associated malignancies are considered attractive targets for immunotherapy because viral proteins are strong immune stimulants. From this perspective, cervical cancer may be a good candidate for immunotherapy because cervical cancer is associated with persistent human papillomavirus infection, which accounts for as much as 86% of the global incidence of cervical cancer. In addition, approximately 50% of ovarian cancer patients exhibit homologous recombination deficiency in the DNA repair system, which could potentiate immunogenicity for anticancer immunotherapy. About 22–33% of endometrial cancers are also known to involve mismatch repair deficiency (MMRd) or high microsatellite instability (MSI-H), which has been confirmed to be a predictive marker of ICI effectiveness. In clinical settings, a combination of pembrolizumab and lenvatinib has been approved in advanced endometrial cancer by the Food and Drug Administration (FDA) based on a promising response rate of 40%. Pembrolizumab has also been approved by the FDA for the management of advanced cervical cancer, with demonstrated anticancer activity. Furthermore, in recurrent ovarian cancer, nivolumab and pembrolizumab have shown anticancer activity as a mono- or in combination with bevacizumab or poly ADP-ribose polymerase inhibitors in several clinical trials.

As described, gynecologic cancers are good candidates for anticancer immunotherapy; therefore, more clinical studies using immunotherapy are warranted in the field of gynecologic cancer. Currently, real-world data regarding ICIs in gynecologic cancers are limited. In the present study, we retrospectively evaluated the efficacy and safety of pembrolizumab among patients with recurrent gynecologic cancers in real-world practice.

MATERIALS AND METHODS

Study population

We performed a retrospective study of patients with recurrent or refractory gynecologic malignancies who were treated with pembrolizumab at CHA Bundang Medical Center between February 2016 and March 2020. In Korea, pembrolizumab can be prescribed to patients with any type of solid tumor that exhibits MSI-H and/or MMRd, recurrent cervical cancer, and recurrent ovarian cancer expressing PD-L1.

The inclusion criteria were as follows: 1) pathologic diagnosis of a gynecologic malignancy, including the uterine cervix, ovaries, or uterine corpus; 2) tumor progression during or after one or more lines of standard treatment, irrespective of Eastern Cooperative Oncology Group (ECOG) performance status, and 3) at least one cycle of treatment with pembrolizumab. The patients received 200 mg of pembrolizumab as 30-minute intravenous infusions every 3 weeks until disease progression, unacceptable toxicities, or patient withdrawal. The present study was approved by our Institutional Review Board (CHA IRB 2018-09-019).

Evaluation of efficacy and safety

Abdomino-pelvic and/or chest computed tomography (CT) scans were performed every 9 weeks. In addition, pelvic magnetic resonance imaging, whole body bone scans, or positron emission tomography CT scans were performed if indicated. If clinical symptoms deteriorated, imaging studies were performed immediately. Tumor responses were determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The primary efficacy endpoint was the objective response rate (ORR) and safety. Safety was assessed by reviewing medical records, including review of systems, physical examination findings, and blood tests prior to each treatment cycle. Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Secondary end points included the duration of response, defined as the time from response to tumor progression or death, whichever occurred first; progression-free survival (PFS), defined as the time from start of pembrolizumab to tumor progression or death, whichever occurred first; and OS, defined as the time from the start of treatment to death from any cause. The efficacy and safety profile analyses included all patients who received at least one cycle of pembrolizumab.

Determination of PD-L1 expression

Tumor PD-L1 expression was evaluated using the PD-L1 IHC 22C3 antibody (Dako, Santa Clara, CA, USA) to determine the tumor proportion score (TPS), defined as the percentage of viable tumor cells with staining at any intensity, or using the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, USA) to determine the combined positive score (CPS), defined as the ratio of the number of PD-L1 positive cells (tumor cells, lymphocytes, and macrophages) to the total number of viable tumor cells multiplied by 100. PD-L1 positivity was defined as a TPS ≥1% or CPS ≥1.

Statistical analysis

Efficacy and safety profile analyses included all patients who received at least one cycle of pembrolizumab. ORR point esti-
mates were accompanied by 95% confidence intervals (CIs) using the Clopper-Pearson exact method based on a binomial distribution. Patients without response data were considered as non-responders. The duration of response, PFS, and OS were estimated using the Kaplan-Meier method. All statistical calculations were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Analysis items with \( p \) values less than 0.05 were considered statistically significant.

**RESULTS**

**Patient characteristics**

Thirty-one patients treated with pembrolizumab were included. The primary disease sites were the uterine cervix (n=18), ovary (n=8), and uterine corpus (n=5). The median age at diagnosis was 53.0 years (range, 30–79); 48.4% (15/31) of patients had an ECOG performance status of 2 or 3; and 77.5% (24/31) had stage III or IV disease at the initial diagnosis. The median number of prior chemotherapy lines, including neoadjuvant chemotherapy, was 2 (range, 1–6). As of March 31, 2020, the date of data cutoff, the median follow-up time was 4.7 months (range, 0.2–35.3). Twenty-one patients (72.4%) had discontinued pembrolizumab, most commonly due to disease progression (41.9%, n=13) (Fig. 1). The median number of pembrolizumab cycles was 6 (range, 1–30). The baseline characteristics are listed in Table 1.

**Efficacy**

The overall ORR was 22.6% (95% CI: 10.0–41.1), with a complete response in 2 patients (6.5%) and a partial response in 5 patients (16.1%). According to tumor types, the ORRs were 22.3% (4 of 18 patients) for cervical cancer, 12.5% (1 of 8 patients) for ovarian cancer, and 40% (2 of 5 patients) for endometrial cancer (Table 2). The median duration of response was not reached (range, 8.8–not reached). The disease control rate was 38.7% (95% CI: 21.8–57.8), including 7 responders and 5 patients with stable disease (Table 2). A clinical summary of the seven responders is provided in Supplementary Table 1 (only Table 1.

| Characteristics                        | n (%)   |
|----------------------------------------|---------|
| Median age (range), yr                 | 53.0 (30–79) |
| ECOG performance status                |         |
| 0                                      | 4 (12.9) |
| 1                                      | 12 (38.7) |
| 2                                      | 6 (19.4) |
| 3                                      | 9 (29.0) |
| FIGO stage at diagnosis                |         |
| I                                      | 2 (6.5)  |
| II                                     | 5 (16.1) |
| III                                    | 18 (58.1) |
| IV                                     | 6 (19.4) |
| PD-L1 expression status*               |         |
| ≥1                                     | 23 (74.2) |
| <1                                     | 2 (6.5)  |
| Not tested                             | 6 (19.4) |
| Histology                              |         |
| Uterine cervix                         | 18 (58.1) |
| Squamous cell carcinoma                | 12 (66.7) |
| Adenocarcinoma                         | 4 (22.2) |
| Adenosquamous cell carcinoma           | 2 (11.1) |
| Ovary                                  | 8 (24.1) |
| High-grade serous carcinoma            | 6 (75.0) |
| Endometrioid adenocarcinoma            | 1 (12.5) |
| Clear cell carcinoma                   | 1 (12.5) |
| Uterine corpus                         | 5 (16.1) |
| High-grade serous carcinoma            | 1 (20.0) |
| Carcinosarcoma                         | 1 (20.0) |
| Neuroendocrine carcinoma               | 1 (20.0) |
| Leiomyosarcoma                         | 1 (20.0) |
| Dedifferentiated carcinoma             | 1 (20.0) |
| Target lesion size, median (range), mm | 119.0 (9.0–405.0) |
| Time from diagnosis to pembrolizumab therapy (yr) |         |
| ≤1                                     | 6 (19.4) |
| >1                                     | 25 (80.6) |
| Prior lines of chemotherapy             |         |
| 1                                      | 7 (22.6) |
| 2                                      | 10 (32.3) |
| 3                                      | 3 (9.7)  |
| 4                                      | 8 (25.8) |
| ≥5                                     | 3 (9.7)  |

ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; PD-L1, programmed death-ligand 1.

* Determined using the tumor proportion score or the combined positive score.
The best percentage change in the target lesion from baseline and changes in tumor burden over time for the 22 patients who underwent one or more evaluable post-baseline imaging assessments are shown in Fig. 2. At the time of data cutoff, 19 (61.3%) patients in the total population had experienced disease progression or death. The median PFS was 2.5 months (95% CI: 1.7–not reached), and the estimated PFS rate at 6 months was 41.2%. 14 (45.2%) patients died. The median OS was 14.3 months (95% CI: 3.7–not reached). The OS rates estimated at 6 and 12 months were 63.7% and 50.9%, respectively (Supplementary Fig. 1, only online). One (Cx001) of the seven responders had died as of the data cutoff date (Supplementary Table 1, only online).

Adverse events
AEs occurred in 20 patients (64.5%), and only 3 (9.7%) had grade ≥3 AEs (Table 3). The most common AEs of any grade were hypothyroidism (12.9%), anemia (12.9%), and fatigue (9.7%). There was one case (Cx001) of suspected treatment-related mortality. Patient Cx001 began to receive pembrolizumab with an indwelling Foley catheter, having undergone percutaneous nephrostomy in the left kidney and colostomy with an ECOG performance status of 2. Twenty days after initial pembrolizumab, interstitial pulmonary infiltrates, implying combined interstitial lung disease and pulmonary edema, occurred abruptly, and the patient died of respiratory failure the next day (Supplementary Fig. 2, only online). There were no other treatment-related fatal AEs. Most AEs were manageable.

Table 2. Antitumor Activities of Pembrolizumab Assessed by RECIST v1.1 (n=31)

| Antitumor activity | Total (n=31) | Cervix (n=18) | Ovary (n=8) | Uterus (n=5) |
|--------------------|--------------|---------------|------------|-------------|
| Best overall response |              |               |            |             |
| CR                 | 2 (6.5)      | 1 (5.6)       | 0          | 1 (20.0)    |
| PR                 | 5 (16.1)     | 3 (16.7)      | 1 (12.5)   | 1 (20.0)    |
| SD                 | 5 (16.1)     | 3 (16.7)      | 2 (25.0)   | 0           |
| PD                 | 13 (41.9)    | 8 (44.4)      | 2 (25.0)   | 3 (60.0)    |
| Could not be assessed | 6 (19.4)    | 3 (16.7)      | 3 (37.5)   | 0           |
| ORR                | 22.6         |               |            |             |
| DCR                | 38.7         |               |            |             |
| Time to response, median | 1.9 [1.4–5.7] |               |            |             |
| Duration of response, median | NR [8.8–NR] |               |            |             |

Estimated number of patients with duration of response (n=7)
- >6 months: 5
- >12 months: 4
- >18 months: 2

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate, DCR, disease control rate; NR, not reached. Data are presented as n (%).

Fig. 2. Antitumor activity of pembrolizumab. (A) Waterfall plot showing the distribution of best percentage changes in the sum of target lesion size from baseline according to RECIST version 1.1 (n=22). (B) Kinetics of changes in tumor burden over time with pembrolizumab treatment.

https://doi.org/10.3349/ymj.2020.61.10.844
DISCUSSION

To the best of our knowledge, this is one of the first real-world studies of gynecologic cancers with pembrolizumab. We demonstrated that pembrolizumab therapy is a feasible option for heavily treated gynecologic cancer patients with poor performance status in real-world practice. Notably, pembrolizumab therapy was effective in patients with poor performance status that would be excluded from well-designed clinical trials.

The overall ORR among our 18 cervical cancer patients was 22% (4/18), which is comparable to the rate of 4–26% reported in previous studies as shown in Table 4.8,21–23 The ORRs for ovarian cancer (13%) and endometrial cancer (40%) in the present study were also similar to previously reported data: 10–33% for ovarian cancer14,16,24,25 and 13–57% for endometrial cancer14,24,26 as shown in Table 4. Prospective clinical trials and real-world experience studies differ on a couple of points. First, in prospective studies, only patients with good performance status (ECOG ≤1) are enrolled. However, in this study, approximately half of the patients (15/31) showed poor general condition (ECOG ≥2). Second, in prospective studies, a lower proportion of patients (31–38%) receive three or more lines of chemotherapy.8,21 However, in the present study, 45% of the patients had already received three or more lines of chemotherapy. Moreover, one prospective study only enrolled patients harboring MSI-H or MMRd, which are generally accepted predictive biomarkers.14 Therefore, it is difficult to directly compare our results with those of prospective trials. Despite the worse patient conditions and later line of therapy in our study, the comparable outcomes were notable as real-world data. Overall outcomes, including excellent responders (Ut002, Cx006, and Ov004) with poor performance status who received pembrolizumab (Supplementary Table 1, only online), suggest that ICI therapy might be effective among heavily treated patients in late stages of gynecological cancer.

Regarding AEs, the patients in this study were less likely to have frequent and severe AEs than patients enrolled in clinical trials, attributable to their worse performance status. However, AEs might have been underestimated in this study because not all grades of AEs could be monitored, particularly, if they were of lower grades in retrospective studies. Although there was one case of suspected treatment-related mortality, AEs were mostly manageable. This suggests that patients with advanced gynecologic cancer should not be excluded from ICI therapy simply because of poor performance status. Nevertheless, since the patient who died had several comorbidities, including an indwelling Foley catheter, percutaneous nephrostomy, and colostomy, we should exercise caution in administering ICI therapy to patients with comorbidities.

The discovery of predictive biomarkers is an urgent need for ICI therapy. MMRd/MSI-H, tumor mutational burden, PD-L1 expression, and tumor-infiltrating lymphocytes have recently been studied as potential biomarkers of ICI therapy. In particular, MMRd/MSI-H has been confirmed to be a predictive biomarker for favorable responses to pembrolizumab, leading to FDA agnostic approval for pembrolizumab therapy in any site phase drug n rate of pd-l1 expression orr a/e >gr3 study, reference year

| Site     | Phase | Drug               | N   | Rate of PD-L1 expression | ORR   | A/E >gr3 | Study, reference | Year |
|----------|-------|--------------------|-----|--------------------------|-------|----------|-----------------|------|
| Cervix   | II    | Pembrolizumab 10 mg/kg q2w | 24  | 100%                     | 17%   | 5 (21%)  | Keynote028β     | 2017 |
|          | III   | Pembrolizumab 200 mg q3w  | 98  | 84%                      | 12%   | 12 (12%) | Keynote158β     | 2019 |
|          | III   | Nivolumab 240 mg q2w   | 19  | 63%                      | 26%   | 4 (21%)  | Checkmate358β   | 2019 |
|          | II    | Nivolumab 3 mg/kg q2w  | 25  | 77%                      | 4%    | 6 (24%)  | NRG-GY002β      | 2020 |
| Ovary    | II    | Nivolumab 1 or 3 mg/kg q2w | 20  | 80%                      | 15%   | 8 (40%)  | Keynote028β      | 2015 |
|          | II    | Pembrolizumab 10 mg/kg q2w | 26  | 100%                     | 12%   | 1 (4%)   | Keynote028β      | 2016 |
|          | II    | Avelumab 10 mg/kg q2w   | 125 | 61%                      | 10%   | 9 (7%)   | JAVELIN17β      | 2019 |
|          | II    | Pembrolizumab 200 mg q3w | 15  | N/A*                     | 33%   | N/A      | Keynote158β      | 2020 |
| Endometrium | II  | Pembrolizumab 10 mg/kg q2w | 24  | 100%                     | 13%   | 4 (17%)  | Keynote028β       | 2017 |
|          | II    | Pembrolizumab 10 mg/kg q2w | 15  | N/A*                     | 53%   | N/A      | Keynote158β      | 2017 |
|          | II    | Pembrolizumab 200 mg q3w | 49  | N/A*                     | 57%   | N/A      | Keynote158β      | 2020 |

ORR, objective response rate; A/E, adverse event; N/A, non-available.

* All tumors showed either high microsatellite instability or mismatch repair deficiency. † Rate of ≥1 PD-L1 expression assessed using the combined positive score.
type of solid tumor, including gynecologic cancers. In the present study, we analyzed predictive factors for responses. No clinicopathologic factors, including tumor type, age, ECOG performance status, number of prior lines of chemotherapy, and PD-L1 status, predicted response (data not shown). This is probably because of the small number of patients and heterogeneous tumor group.

The limitations of this study include its retrospective design, small sample size, heterogeneous tumor types, and short follow-up period. Also, we did not perform a response evaluation based on immune RECIST or immune-related RECIST to assess the immune response. This could be regarded as a limitation of the retrospective study. Therefore, it is essential to prospectively collect clinical data of patients who receive ICI therapy according to each type of gynecological cancer from multiple centers.

Collectively, in real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials. Further studies are warranted to discover predictive biomarkers for ICIs in gynecologic cancer.

ACKNOWLEDGEMENTS

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C1559).

AUTHOR CONTRIBUTIONS

Conceptualization: Min Chul Choi, Yong Wha Moon, and Won Duk Joo. Data curation: all authors. Formal analysis: Min Chul Choi. Funding acquisition: Yong Wha Moon. Investigation: Min Chul Choi. Methodology: Min Chul Choi. Project administration: Min Chul Choi and Yong Wha Moon. Resources: Min Chul Choi. Software: Min Chul Choi. Supervision: Min Chul Choi, Yong Wha Moon, and Won Duk Joo. Validation: Min Chul Choi, Yong Wha Moon, and Won Duk Joo. Visualization: Min Chul Choi. Writing—original draft: Min Chul Choi and Yong Wha Moon. Writing—review & editing: all authors. Approval of final manuscript: all authors.

ORCID iDs

Min Chul Choi https://orcid.org/0000-0003-4509-6731
Yong Wha Moon https://orcid.org/0000-0002-7943-974X
Sang Geun Jung https://orcid.org/0000-0002-0635-6994
Hyun Park https://orcid.org/0000-0002-7825-9165
Won Duk Joo https://orcid.org/0000-0003-4637-9846
Seung Hun Song https://orcid.org/0000-0002-9192-8884
Chan Lee https://orcid.org/0000-0003-1654-4398
Gwangil Kim https://orcid.org/0000-0002-4867-9003
Kyoung Ah Kim https://orcid.org/0000-0003-4997-4829

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71:1397-412.
3. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog Tj, Contemporary management of endometrial cancer. Lancet 2012;379:1352-60.
4. Motzer RJ, Escudier B, McDermott DE, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;372:1803-13.
5. Robert C, Schachter J, Long GV, Arance A, Grob J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32.
6. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.
7. Makker V, Rasco D, Vogelzang NJ, Bross MD, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20:711-8.
8. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2019;37:1470-8.
9. Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res 2017;27:59-73.
10. Almamy L, de Sanjosé S, Tous S, Quint W, Vallesjos C, Shin HR, et al. Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int J Cancer 2014;135:88-95.
11. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:699-705.
12. Dai Y, Sun C, Feng Y, Jia Q, Zhu B. Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. J Cell Mol Med 2018;22:3979-86.
13. Dudley JC, Lin MT, Le DT, Eshleman JR. Multisatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016;22:813-20.
14. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-13.
15. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;33:4015-22.
16. Varga A, Pihá-Paul S, Otta PA, Mehnert JM, Berton-Rigaud D, Moresky A, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol 2019;152:243-50.
17. Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1731-8.
18. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5:1141-9.
19. Normann MC, Türzer M, Diep LM, Oldenburg J, Gajdzik B, Solheim O, et al. Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. J Gynecol Oncol 2019; 30:e56.

20. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 2016;62:132-7.

21. Frenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol 2017;35:4035-41.

22. Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol 2019; 37:2825-34.

23. Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol 2020;157:161-6.

24. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020;38:1-10.

25. Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019;5:393-401.

26. Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results From the KEYNOTE-028 Study. J Clin Oncol 2017;35:2535-41.